ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model

Lin, Jinrong; Qu, Zhao*; Pu, Huanhuan; Shen, Li-Sha; Yi, Xianguo; Lin, Yu-Shan; Gong, Rui-Hong; Chen, Guo-Qing*; Chen, Sibao*河北医科大学; 中国医学科学院; 中国医学科学院北京协和医院
MOLECULES2023-12DOI: 10.3390/molecules28237701
10阅读
引用收藏
分享

摘要

Due to its intricate heterogeneity, high invasiveness, and poor prognosis, triple-negative breast cancer (TNBC) stands out as the most formidable subtype of breast cancer. At present, chemotherapy remains the prevailing treatment modality for TNBC, primarily due to its lack of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth receptor 2 (HER2). However, clinical chemotherapy for TNBC is marked by its limited efficacy and a pronounced incidence of adverse effects. Consequently, there is a pressing need for novel drugs to treat TNBC. Given the rich repository of diverse natural compounds in traditional Chinese medicine, identifying potential anti-TNBC agents is a viable strategy. This study investigated lasiokaurin (LAS), a natural diterpenoid abundantly present in Isodon plants, revealing its significant anti-TNBC activity both in vitro and in vivo. Notably, LAS treatment induced cell cycle arrest, apoptosis, and DNA damage in TNBC cells, while concurrently inhibiting cell metastasis. In addition, LAS effectively inhibited the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway and signal transducer and activator of transcription 3 (STAT3), thus establishing its potential for multitarget therapy against TNBC. Furthermore, LAS demonstrated its ability to reduce tumor growth in a xenograft mouse model without exerting detrimental effects on the body weight or vital organs, confirming its safe applicability for TNBC treatment. Overall, this study shows that LAS is a potent candidate for treating TNBC.

学科与关键词

关键词
lasiokaurinisodontriple-negative breast cancerPI3K/Akt/mTORSTAT3
相关
加载中…
  • Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
    Han, Rui*; Yang, Hongxing; Ling, Changquan; Lu, Lingeng*Cancer Cell International, 2022, 22(1): 368.被引 6
  • Inhibition of growth and metastasis of triple-negative breast cancer targeted by Traditional Chinese Medicine Tubeimu in orthotopic mice models.
    Wang, Jingxiao; Yang, Xinjie; Han, Haibo; Wang, Limin; Bao, Weiqian; Wang, Shanshan; Hoffman, Robert M; Yang, Meng; Qi, Hui; An, Chao; Hu, KaiwenChin J Cancer Res, 2018, 30(1): 112-121.
  • Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF? signaling pathway
    Zhang, Yuzhu; Chen, Jing; Mi, Dazhao; Ling, Jun; Li, Huachao; He, Peng; Liu, Ning; Chen, Qianjun*; Chen, Yihua*; Huang, Luqi*Cancer Letters, 2023, 560: 216142.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
MOLECULES
发表日期
2023-12
卷期
第 28 卷, 第 23 期
页码
7701
DOI
10.3390/molecules28237701
语言
ENGLISH
成果收录
SCIE
资助标注
Research Centre for Chinese Medicine Innovation of the Hong Kong Polytechnic University

作者

  • L

    Lin, Jinrong (第一作者)

    chinese acad med sci · inst med · peking union med coll

  • Q

    Qu, Zhao (通讯)

    china three gorges univ

查看全部 9 位作者收起作者
  • P

    Pu, Huanhuan

    chinese acad med sci · inst med · peking union med coll

  • S

    Shen, Li-Sha

    chongqing acad chinese mat med

  • Y

    Yi, Xianguo

  • L

    Lin, Yu-Shan

    hong kong polytech univ

  • G

    Gong, Rui-Hong

    hong kong polytech univ

  • C

    Chen, Guo-Qing (通讯)

    hong kong polytech univ

  • C

    Chen, Sibao (通讯)

    chinese acad med sci · inst med · peking union med coll · hong kong polytech univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417